Trial Profile
An Exploratory Study of Ranibizumab (Lucentis) for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema Which Has Proven Refractory or Ineligible to Standard Treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Apr 2019
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal oedema; Uveitis
- Focus Therapeutic Use
- Acronyms The LIMO study
- 04 Jul 2016 Status changed from recruiting to completed.
- 15 Apr 2015 According to ClinicalTrials.gov the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2012).
- 15 Apr 2015 New trial record